Mpm Bioimpact LLC
· New
Change
+4.8M
Date
Q1 2026
AK
| Investor | Type | Est. change | Change | Δ Own | Date | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Mpm Bioimpact LLC
· New
Change
+4.8M
Date
Q1 2026
|
Mpm Bioimpact LLC | New· Q1 2026 | – | +4.8M | – | Q1 2026 | |||||
|
Ecor1 Capital, LLC
· New
Change
+4.8M
Date
Q1 2026
|
Ecor1 Capital, LLC | New· Q1 2026 | – | +4.8M | – | Q1 2026 | |||||
|
Blue Owl Capital Holdings LP
· New
Change
+3.2M
Date
Q1 2026
|
Blue Owl Capital Holdings LP | New· Q1 2026 | – | +3.2M | – | Q1 2026 | |||||
|
Wellington Management Group LLP
· New
Change
+2.3M
Date
Q1 2026
|
Wellington Management Group LLP | New· Q1 2026 | – | +2.3M | – | Q1 2026 | |||||
|
T. Rowe Price Investment Management, Inc.
· New
Change
+2.1M
Date
Q1 2026
|
T. Rowe Price Investment Management, Inc. | New· Q1 2026 | – | +2.1M | – | Q1 2026 | |||||
|
BlackRock
· New
Change
+2.1M
Date
Q1 2026
|
BlackRock | New· Q1 2026 | – | +2.1M | – | Q1 2026 | |||||
|
Rtw Investments, LP
· New
Change
+1.6M
Date
Q1 2026
|
Rtw Investments, LP | New· Q1 2026 | – | +1.6M | – | Q1 2026 | |||||
|
T. Rowe Price Associates
· New
Change
+1.6M
Date
Q1 2026
|
T. Rowe Price Associates | New· Q1 2026 | – | +1.6M | – | Q1 2026 | |||||
|
Ra Capital Management, L.P.
· New
Change
+1.5M
Date
Q1 2026
|
Ra Capital Management, L.P. | New· Q1 2026 | – | +1.5M | – | Q1 2026 | |||||
|
Janus Henderson Group PLC
· New
Change
+1.5M
Date
Q1 2026
|
Janus Henderson Group PLC | New· Q1 2026 | – | +1.5M | – | Q1 2026 | |||||
|
Vanguard
· New
Change
+1.1M
Date
Q1 2026
|
Vanguard | New· Q1 2026 | – | +1.1M | – | Q1 2026 | |||||
|
Baker Bros. Advisors LP
· New
Change
+996K
Date
Q1 2026
|
Baker Bros. Advisors LP | New· Q1 2026 | – | +996K | – | Q1 2026 | |||||
|
Octagon Capital Advisors LP
· New
Change
+961K
Date
Q1 2026
|
Octagon Capital Advisors LP | New· Q1 2026 | – | +961K | – | Q1 2026 | |||||
|
Merck & Co., Inc.
· New
Change
+953K
Date
Q1 2026
|
Merck & Co., Inc. | New· Q1 2026 | – | +953K | – | Q1 2026 | |||||
|
Eventide Asset Management, LLC
· New
Change
+507K
Date
Q1 2026
|
Eventide Asset Management, LLC | New· Q1 2026 | – | +507K | – | Q1 2026 | |||||
| Insider | Title | Type | Price | Qty | Value | Owned | ΔOwn | Trade date | Filed date | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Herrmann Ken
· Director
Sell
−$77K
|
Herrmann Ken | Director | Sell | $25.21 | −3K | −$77K | 0 | −100.0% | Jul 17, 2026 | Jul 20, 2026 | |||||||||
|
Herrmann Ken
· Director
2 operations
0
|
Herrmann Ken | Director | 2 operations | $0.08 | 0 | – | 4K | – | Jul 17, 2026 | Jul 20, 2026 | |||||||||
|
Ron-Bigger Shulamit
· Officer
3 operations
−$1.4M
|
Ron-Bigger Shulamit | Officer | 3 operations | $27.13–$28.75 | −50K | −$1.4M | 0 | −100.0% | Jul 8, 2026 | Jul 10, 2026 | |||||||||
|
Ron-Bigger Shulamit
· Officer
2 operations
0
|
Ron-Bigger Shulamit | Officer | 2 operations | $3.66 | 0 | – | 218K | – | Jul 8, 2026 | Jul 10, 2026 | |||||||||
|
Czibere Akos
· Officer
3 operations
−$1.4M
|
Czibere Akos | Officer | 3 operations | $27.13–$28.71 | −50K | −$1.4M | 0 | −100.0% | Jul 8, 2026 | Jul 10, 2026 | |||||||||
|
Czibere Akos
· Officer
2 operations
0
|
Czibere Akos | Officer | 2 operations | $4.95 | 0 | – | 221K | – | Jul 8, 2026 | Jul 10, 2026 | |||||||||
|
Gormley Glenn
· Director
Grant (A)
38K
|
Gormley Glenn | Director | Grant (A) | – | 38K | – | 38K | – | Apr 15, 2026 | Apr 16, 2026 | |||||||||
|
Foley Todd
· Director, 10% Owner
Buy
+$4.2M
|
Foley Todd | Director, 10% Owner | Buy | $18.00 | +233K | +$4.2M | 4.2M | – | Jan 12, 2026 | Jan 14, 2026 | |||||||||
|
Foley Todd
· Director, 10% Owner
6 operations
-11.2M
|
Foley Todd | Director, 10% Owner | 6 operations | – | -11.2M | – | 0 | – | Jan 12, 2026 | Jan 14, 2026 | |||||||||
|
Mpm Oncology Innovations Fund LP
· 10% Owner
Buy
+$20M
|
Mpm Oncology Innovations Fund LP | 10% Owner | Buy | $18.00 | +1.1M | +$20M | 10.3M | – | Jan 12, 2026 | Jan 14, 2026 | |||||||||
|
Mpm Oncology Innovations Fund LP
· 10% Owner
6 operations
-24.7M
|
Mpm Oncology Innovations Fund LP | 10% Owner | 6 operations | – | -24.7M | – | 0 | – | Jan 12, 2026 | Jan 14, 2026 | |||||||||
|
Gadicke Ansbert
· 10% Owner
Buy
+$20M
|
Gadicke Ansbert | 10% Owner | Buy | $18.00 | +1.1M | +$20M | 10.3M | – | Jan 12, 2026 | Jan 14, 2026 | |||||||||
|
Gadicke Ansbert
· 10% Owner
6 operations
-24.7M
|
Gadicke Ansbert | 10% Owner | 6 operations | – | -24.7M | – | 0 | – | Jan 12, 2026 | Jan 14, 2026 | |||||||||
|
Nodelman Oleg
· Director
2 operations
+$40M
|
Nodelman Oleg | Director | 2 operations | $18.00 | +2.2M | +$40M | 347K | – | Jan 12, 2026 | Jan 12, 2026 | |||||||||
|
Nodelman Oleg
· Director
10 operations
-10.2M
|
Nodelman Oleg | Director | 10 operations | – | -10.2M | – | 0 | – | Jan 12, 2026 | Jan 12, 2026 | |||||||||
N
A
M
G
A
A
68 reporting institutions disclosed AKTS position changes in the Q1 2026 snapshot.
For each manager, WhoBought compares accepted consecutive 13F share counts. Share change is current shares minus prior shares. Estimated dollar change is that signed share change multiplied by the split-adjusted quarter-mean close. The activity table on this page uses Q1 2026.
An investor crossing 5% of a share class generally files Schedule 13D for activist intent or Schedule 13G for a passive position. The technical form names appear here rather than in the activity rows.
Ownership and institutional activity come from SEC Form 13F filings. Insider activity comes from SEC Form 4, and large-shareholder activity from SEC Schedules 13D and 13G. FMP supplies price data only. Company logos use the local verified Parqet cache with one shared fallback.
Form 13F is a quarterly disclosure and is normally filed after the quarter ends. Every ownership and activity value therefore names its represented period; it is not presented as a live position.
A muted dash marks a missing table value. It means the filing omitted the value, comparable data is unavailable, or no prior position exists for comparison.